SCD and Parkinson disease: With direct clinical relevance to DAergic neurodegeneration in PD, we observe an increase in striatal DA levels and TH+ nerve terminals coupled with motor improvements in Gba1 mutant mice undergoing prolonged SCD inhibitor treatment.